United Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . United Therapeutics
UTHR Stock  USD 502.71  13.02  2.66%   
United Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing United Therapeutics' valuation are provided below:
Gross Profit
2.8 B
Profit Margin
0.4065
Market Capitalization
22.7 B
Enterprise Value Revenue
5.8387
Revenue
3.1 B
There are over one hundred nineteen available fundamental trend indicators for United Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check United Therapeutics' current fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 01/07/2026, Market Cap is likely to grow to about 15.1 B. Also, Enterprise Value is likely to grow to about 13.8 B

United Therapeutics Total Revenue

3.47 Billion

Check United Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among United Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 87.5 M, Total Revenue of 3.5 B or Gross Profit of 3.1 B, as well as many indicators such as Price To Sales Ratio of 6.06, Dividend Yield of 0.0114 or PTB Ratio of 4.07. United financial statements analysis is a perfect complement when working with United Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with United Stock
Check out the analysis of United Therapeutics Correlation against competitors.
To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

United Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets8.9 B8.5 B4.1 B
Slightly volatile
Short and Long Term Debt Total296.5 M345 M388.3 M
Slightly volatile
Other Current Liabilities521.8 M496.9 M317.2 M
Slightly volatile
Total Current Liabilities891.3 M848.8 M458.5 M
Slightly volatile
Total Stockholder Equity7.8 B7.4 B3.3 B
Slightly volatile
Property Plant And Equipment Net1.5 B1.4 B721 M
Slightly volatile
Accounts Payable10 M6.9 M10 M
Slightly volatile
Cash2 B2 B851.1 M
Slightly volatile
Non Current Assets Total4.2 B4 B2 B
Slightly volatile
Non Currrent Assets Other268.2 M255.4 M144.1 M
Slightly volatile
Cash And Short Term Investments3.9 B3.8 B1.7 B
Slightly volatile
Net Receivables337.3 M321.2 M195.2 M
Slightly volatile
Common Stock Shares Outstanding50.8 M55.8 M47.8 M
Pretty Stable
Liabilities And Stockholders Equity8.9 B8.5 B4.1 B
Slightly volatile
Non Current Liabilities Total266.8 M209.2 M367 M
Slightly volatile
Total Liabilities563.3 M1.1 B792.8 M
Slightly volatile
Total Current Assets4.7 B4.5 B2.1 B
Slightly volatile
Good Will39 M37.1 M21.3 M
Slightly volatile
Common Stock Total Equity531.1 K805 K650.1 K
Slightly volatile
Short Term Investments1.9 B1.8 B837.6 M
Slightly volatile
Property Plant And Equipment Gross2.1 B2 B886 M
Slightly volatile
Short Term Debt362.2 M345 M269.8 M
Slightly volatile
Intangible Assets96.1 M91.5 M52.9 M
Slightly volatile
Common Stock553.7 K920 K664.1 K
Slightly volatile
Other Liabilities60.5 M88.3 M86.2 M
Very volatile
Other Assets284.7 M475.5 M383.8 M
Slightly volatile
Inventory190.7 M181.6 M94.6 M
Slightly volatile
Property Plant Equipment1 B990.7 M639.2 M
Slightly volatile
Current Deferred Revenue395.8 M377 M289.5 M
Slightly volatile
Preferred Stock Total Equity17.5 M22.1 M18.6 M
Pretty Stable
Net Tangible Assets5.7 B5.5 B2.9 B
Slightly volatile
Warrants20 M22.1 M20 M
Very volatile
Long Term Debt Total469.1 M920 M445.9 M
Slightly volatile
Capital Surpluse1.9 B2.7 B1.9 B
Slightly volatile
Long Term Investments1.8 B1.7 B836.9 M
Slightly volatile
Non Current Liabilities Other106 M209.2 M106.1 M
Slightly volatile
Deferred Long Term Asset Charges133.2 M86.1 M137.9 M
Slightly volatile
Short and Long Term Debt244.2 M345 M242.7 M
Slightly volatile
Net Invested Capital5.1 B7.8 B3.9 B
Slightly volatile
Net Working Capital2.3 B3.6 B1.7 B
Slightly volatile
Capital Stock684 K720 K10.9 M
Slightly volatile

United Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue3.5 B3.3 B1.7 B
Slightly volatile
Gross Profit3.1 B3 B1.5 B
Slightly volatile
Other Operating Expenses1.8 B1.7 B948.6 M
Slightly volatile
Research Development580.8 M553.1 M373.4 M
Slightly volatile
Total Operating Expenses1.4 B1.4 B789.6 M
Slightly volatile
Selling General Administrative654.8 M623.6 M341.1 M
Slightly volatile
Cost Of Revenue374 M356.2 M159.1 M
Slightly volatile
Selling And Marketing Expenses82.3 M86.7 M271.3 M
Slightly volatile
Discontinued Operations5.6 K6.3 K6.9 K
Slightly volatile
Interest Income240.4 M229 M60.9 M
Slightly volatile
Reconciled Depreciation53.6 M83.4 M43.7 M
Slightly volatile

United Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1.5 B1.4 B698.4 M
Slightly volatile
Capital Expenditures297.6 M283.5 M120.7 M
Slightly volatile
End Period Cash Flow2 B2 B852.3 M
Slightly volatile
Issuance Of Capital Stock3.1 M3.5 M3.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.066.3764.0132
Slightly volatile
Dividend Yield0.01140.01290.014
Slightly volatile
PTB Ratio4.072.853.1161
Slightly volatile
Days Sales Outstanding38.7140.7465.6076
Slightly volatile
Book Value Per Share13512867.4982
Slightly volatile
PB Ratio4.072.853.1161
Slightly volatile
EV To Sales5.525.8259.9855
Slightly volatile
Inventory Turnover1.21.771.6095
Very volatile
Days Of Inventory On Hand332214279
Pretty Stable
Payables Turnover48.7846.4622.9525
Slightly volatile
Sales General And Administrative To Revenue0.210.220.9283
Slightly volatile
Average Inventory2.4 M4 M4.1 M
Very volatile
Research And Ddevelopement To Revenue0.180.194.7369
Slightly volatile
Capex To Revenue0.09360.09850.4017
Slightly volatile
Cash Per Share68.365.0536.0605
Slightly volatile
Payout Ratio1.191.341.4642
Slightly volatile
Days Payables Outstanding7.738.1365.4443
Slightly volatile
Income Quality1.061.01.1974
Very volatile
Intangibles To Total Assets0.03320.01750.0211
Very volatile
Current Ratio7.246.045.116
Slightly volatile
Tangible Book Value Per Share13212665.9338
Slightly volatile
Receivables Turnover5.669.277.8739
Slightly volatile
Graham Number275262140
Slightly volatile
Shareholders Equity Per Share13512867.4982
Slightly volatile
Debt To Equity0.03980.04190.1386
Pretty Stable
Capex Per Share5.154.912.4799
Slightly volatile
Revenue Per Share60.1657.2935.4245
Slightly volatile
Interest Debt Per Share4.76.838.406
Slightly volatile
Debt To Assets0.03480.03670.1001
Pretty Stable
Operating Cycle415255347
Slightly volatile
Price Book Value Ratio4.072.853.1161
Slightly volatile
Days Of Payables Outstanding7.738.1365.4443
Slightly volatile
Dividend Payout Ratio1.191.341.4642
Slightly volatile
Ebt Per Ebit1.191.291.0543
Slightly volatile
Effective Tax Rate0.130.20.266
Slightly volatile
Company Equity Multiplier1.11.031.3119
Slightly volatile
Long Term Debt To Capitalization0.04080.0430.1034
Pretty Stable
Total Debt To Capitalization0.0380.040.1159
Pretty Stable
Debt Equity Ratio0.03980.04190.1386
Pretty Stable
Quick Ratio6.915.794.8966
Slightly volatile
Net Income Per E B T0.920.890.7425
Slightly volatile
Cash Ratio3.732.642.0799
Slightly volatile
Days Of Inventory Outstanding332214279
Pretty Stable
Days Of Sales Outstanding38.7140.7465.6076
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.080.940.9024
Very volatile
Price To Book Ratio4.072.853.1161
Slightly volatile
Fixed Asset Turnover1.892.122.2306
Pretty Stable
Debt Ratio0.03480.03670.1001
Pretty Stable
Price Sales Ratio6.066.3764.0132
Slightly volatile
Asset Turnover0.290.350.4357
Slightly volatile
Price Fair Value4.072.853.1161
Slightly volatile

United Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap15.1 B14.4 B10.2 B
Slightly volatile
Enterprise Value13.8 B13.1 B9.6 B
Slightly volatile

United Fundamental Market Drivers

Forward Price Earnings15.949
Cash And Short Term Investments3.3 B

United Upcoming Events

28th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About United Therapeutics Financial Statements

United Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although United Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in United Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on United Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue377 M395.8 M
Total Revenue3.3 B3.5 B
Cost Of Revenue356.2 M374 M
Stock Based Compensation To Revenue 0.06  0.11 
Sales General And Administrative To Revenue 0.22  0.21 
Research And Ddevelopement To Revenue 0.19  0.18 
Capex To Revenue 0.10  0.09 
Revenue Per Share 57.29  60.16 
Ebit Per Revenue 0.43  0.45 

Pair Trading with United Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with United Stock

  0.76AMGN Amgen IncPairCorr

Moving against United Stock

  0.82HPQ HP IncPairCorr
  0.82HD Home DepotPairCorr
  0.82MSFT MicrosoftPairCorr
  0.69PG Procter GamblePairCorr
  0.31DOCKF Beyond Medical TechnPairCorr
The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.
The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY